Skip to main content

Clinical Adoption

IceCure's ProSense Reports 97.5% Response Rate at EUSOBI 2026

IceCure's ProSense Reports 97.5% Response Rate at EUSOBI 2026

Caesarea, Israel – October 13, 2026 -- IceCure Medical (Nasdaq: ICCM) reported 12-month objective response rates of 97.5% among 40 breast cancer patients treated with ProSense® cryoablation plus endocrine therapy, and 91.7% among 24 patients treated with cryoablation alone, at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026 in Maastricht, the Netherlands.

ProSense features in two scientific sessions at the Maastricht meeting

Dr. Lucía Graña-López of Lugo, Spain, presented the clinical potential of cryoablation in "Beyond Biopsy: Image-Guided Therapy in Practice," part of the session "From Target to Treatment: Breast Interventions."

Cold Plasma Healthcare Market to Hit $6.6B by 2032, Growing 12.7%

Cold Plasma Healthcare Market to Hit $6.6B by 2032, Growing 12.7%

London – – October 07, 2026 -- The global cold plasma in healthcare market is projected to climb from $2,873 million in 2025 to $6,634 million by 2032, a compound annual growth rate of 12.7%, according to a new report from Credence Research Inc.

Devices dominate revenue while consumables build recurring streams

Devices accounted for 68.4% of product-segment revenue in 2025, reflecting continued emphasis on installed treatment capacity ahead of scaling consumables and service income. Plasma Jet technology held 39.6% of the technology segment, while Atmospheric Pressure Cold Plasma captured 66.8% of the pressure-type category, favored for bedside and outpatient use without vacuum infrastructure.